Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics granted inducement stock options to purchase 207,150 shares at $18.20 per share to two new employees under its 2026 Inducement Plan. The awards were made October 1, 2026 outside stockholder-approved plans, as permitted under Nasdaq Listing Rule 5635(c)(4), and vest over four years. This is routine hiring-related equity compensation with no bearing on Bicara's pipeline, including its lead program ficerafusp alfa in head and neck squamous cell carcinoma.

•27d ago

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics awarded inducement grants on September 1, 2026 to two new employees under its 2026 Inducement Plan, consisting of non-qualified stock options to purchase 380,575 shares at an exercise price of $23.42 per share. The package includes a 275,000-share option for Gregory Shiferman, the company's newly appointed Chief Legal Officer, with the grants made as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The awards were issued outside stockholder-approved equity plans and were approved by the board's compensation committee of independent directors, vesting one-fourth on the first anniversary of each start date with the remainder in 12 equal quarterly installments.

•1mo ago

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics appointed Jennifer Larson as Chief Financial Officer, effective August 12, 2026, issuing her an inducement grant of options to purchase 285,000 shares. The options have an exercise price of $24.63 per share, equal to the closing price on the grant date, and vest over four years starting on the first anniversary of her employment. The grant was approved by the independent directors under Nasdaq Listing Rule 5635(c)(4) as a material inducement for Ms. Larson to join the company.

•2mo ago

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET

Bicara Therapeutics announced it will report its second quarter 2026 financial results and business updates before the market opens on August 11, 2026. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results, with a live webcast and replay available on its website.

•2mo ago

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics granted non-qualified stock options to purchase 191,425 shares of common stock to four new employees as a material inducement to employment. The options have an exercise price of $28.91 per share, equal to the closing price on July 1, 2026, and were approved under Nasdaq Listing Rule 5635(c)(4). Vesting begins with one-fourth of the shares on the first anniversary of the employee's start date, with the remainder vesting in equal quarterly installments.

•4mo ago

Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

Bicara Therapeutics announced it will report first quarter 2026 financial results and business updates before the market opens on Monday, May 11, 2026. The company will host a conference call to discuss these results at 8:30 a.m. ET on the same day. Event details and registration links are provided for investors to access the live webcast or dial-in.

•5mo ago